COYA 101
Undisclosed (Autologous Treg Cell Therapy)
Not DisclosedPipeline Asset
Key Facts
Indication
Undisclosed (Autologous Treg Cell Therapy)
Phase
Not Disclosed
Status
Pipeline Asset
Company
About Coya Therapeutics
Coya Therapeutics is pioneering a novel approach to treating chronic inflammatory diseases by targeting and enhancing the function of regulatory T cells (Tregs). The company has generated strong proof-of-concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, with its lead biologic candidate, COYA 302, advancing in clinical trials for ALS and Frontotemporal Dementia (FTD). As a public, clinical-stage biotech, Coya is leveraging its multi-modality Treg platform to address significant unmet needs in large neurodegenerative and autoimmune markets.
View full company profile